Biokin unit gets second $250m milestone from Bristol Myers Squibb for iza-bren
百利天恒:全资子公司SystImmune收到百时美施贵宝就“伦康依隆妥单抗”(iza-bren)全球战略合作协议支付的第二笔2.5亿美元里程碑付款,截至目前累计
Shows the Bristol Myers Squibb partnership is still delivering cash to Biokin, with most of the potential payments still ahead.
Sichuan Biokin said its wholly owned subsidiary SystImmune received a second $250m milestone payment from Bristol Myers Squibb under their global partnership on iza-bren, bringing payments received so far to $1.3bn. SystImmune remains eligible for up to $7.1bn in further payments.